G(M2) Ganglioside (Ganglioside GM2)

A glycosphingolipid that accumulates due to a deficiency of hexosaminidase A or B (BETA-N-ACETYLHEXOSAMINIDASES), or GM2 activator protein, resulting in GANGLIOSIDOSES, heredity metabolic disorders that include TAY-SACHS DISEASE and SANDHOFF DISEASE.

Also Known As:

Networked: 179 relevant articles (5 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tsuji, Daisuke: 11 articles (01/2013 - 03/2005)
2.	Itoh, Kohji: 10 articles (10/2011 - 03/2005)
3.	Seyfried, Thomas N: 6 articles (05/2015 - 05/2006)
4.	Caillaud, Catherine: 5 articles (08/2014 - 11/2005)
5.	Sakuraba, Hitoshi: 5 articles (08/2010 - 08/2006)
6.	Yamanaka, Shoji: 5 articles (01/2010 - 03/2003)
7.	Martin, Douglas R: 4 articles (05/2015 - 05/2004)
8.	Platt, Frances M: 4 articles (06/2010 - 08/2003)
9.	Sonnino, Sandro: 3 articles (08/2014 - 11/2005)
10.	Matsuoka, Kazuhiko: 3 articles (10/2011 - 03/2007)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 03/28/1995 - "Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine." 05/15/1989 - "Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells." 04/08/1989 - "Human monoclonal antibody to ganglioside GM2 for melanoma treatment." 01/01/2002 - "Melanoma patients with antibodies against GM2 ganglioside have significantly improved disease-free and overall survival compared to antibody-negative subjects. " 05/01/1994 - "Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside."
2.	Lung Neoplasms (Lung Cancer) 11/09/1998 - "Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice." 04/26/2001 - "Humanized anti-ganglioside GM2 antibody is effective to induce antibody-dependent cell-mediated cytotoxicity in mononuclear cells from lung cancer patients." 05/01/1996 - "Anti-ganglioside GM2 monoclonal antibody-dependent killing of human lung cancer cells by lymphocytes and monocytes." 11/09/1998 - "In this study, we evaluated the therapeutic efficacy of a mouse-human chimeric anti-ganglioside GM2 (GM2) monoclonal antibody (MAb), KM966 against metastasis formation of GM2-positive human lung cancer cells inoculated intravenously (i.v.) into natural killer (NK) cell-depleted severe combined immunodeficient (SCID) mice. " 01/01/2000 - "Human interferon-gamma enhances expression of ganglioside GM2 on human lung cancer cells and their susceptibility for antiganglioside GM2 monoclonal antibody-dependent cellular cytotoxicity."
3.	Neoplasm Metastasis (Metastasis) 11/09/1998 - "In this study, we evaluated the therapeutic efficacy of a mouse-human chimeric anti-ganglioside GM2 (GM2) monoclonal antibody (MAb), KM966 against metastasis formation of GM2-positive human lung cancer cells inoculated intravenously (i.v.) into natural killer (NK) cell-depleted severe combined immunodeficient (SCID) mice. " 12/01/2011 - "Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells." 01/01/2000 - "Immunological circumvention of multiple organ metastases of multidrug resistant human small cell lung cancer cells by mouse-human chimeric anti-ganglioside GM2 antibody KM966." 12/01/2011 - "We examined the antimetastatic effects of the humanized anti-ganglioside GM2 (GM2) antibodies, BIW-8962 and KM8927, compared with the chimeric antibody KM966, in a SCID mouse model of multiple organ metastases induced by GM2-expressing SCLC cells. " 01/10/2003 - "Suppression of lung metastasis of mouse Lewis lung cancer P29 with transfection of the ganglioside GM2/GD2 synthase gene."
4.	Neoplasms (Cancer) 07/15/1989 - "To address systematically this aspect of ganglioside metabolism, we have initiated a study of the structures of the ceramide species of an oligosaccharide-homogeneous human tumor-derived ganglioside, GM2. " 01/01/2015 - "Ganglioside GM2 is a glycolipid that has been shown to be overexpressed in various types of cancer. " 08/27/1999 - "Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo." 04/15/1997 - "Differences in GalNAc-T gene expression between the solid tumors and the cultured tumor cells correlate with the expression of ganglioside GM2. " 05/01/1996 - "Ganglioside GM2 (GM2) frequently appears on the cell surface of human cancers of neuroendocrine origin. "
5.	Sandhoff Disease (Sandhoff's Disease) 05/01/2015 - "The storage of BMP and ganglioside GM2 in brain were reduced similarly following adeno-associated viral-mediated gene therapy in Sandhoff disease mice. " 08/01/2010 - "NgHexA was more efficiently taken up than the wild-type HexA and delivered to lysosomes, where it degraded accumulated substrates including GM2 ganglioside (GM2) when administered to cultured fibroblasts derived from a Sandhoff disease (SD) patient. " 01/01/2001 - "Sandhoff disease is a lysosomal storage disorder characterized by G(M2) ganglioside accumulation in the central nervous system (CNS) and periphery. " 06/11/1996 - "Thus, mutations in either gene encoding its alpha or beta subunits can result in GM2 ganglioside storage and Tay-Sachs or Sandhoff disease, respectively. " 09/26/2000 - "Bone marrow transplantation of Sandhoff disease mice suppressed both the explosive expansion of activated microglia and the neuronal cell death without detectable decreases in neuronal G(M2) ganglioside storage. "

Related Drugs and Biologics

1.	Antibodies
2.	Antigens
3.	Immunoglobulin M (IgM)
4.	QS 21 (QS21)
5.	Hexosaminidase A (Hex A)
6.	Proteins (Proteins, Gene)
7.	Saponins
8.	Interferon-gamma (Interferon, gamma)
9.	Hemocyanin
10.	Doxorubicin (Adriamycin)

Related Therapies and Procedures

1.	Caloric Restriction
2.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
3.	Immunotherapy